Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Wuhan Yzy Biopharma Co. Ltd. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. CHRISTINE J SAOUD is the busiest examiner, currently overseeing 1 pending office action. The distribution of 2 pending office actions across 2 distinct examiners and 2 distinct art units suggests a lack of concentration in the current prosecution, requiring the applicant to manage two separate administrative tracks simultaneously.
Practitioners must manage two separate tracks of communication and technical requirements within the Biotechnology & Pharmaceuticals field. The presence of 2 distinct art units may also imply that the pending applications cover different sub-specialties, requiring unique arguments for each examiner. Since each of the 2 distinct examiners handles exactly half of the pending workload, no single individual has a dominant influence over the entire portfolio. Success in these matters will require a versatile strategy that addresses the specific concerns of CHRISTINE J SAOUD while also satisfying the requirements of the second examiner in a different art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAOUD, CHRISTINE J | 1 | 57.9% | +37.5% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18257749 | ANTI-BCMA ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SAOUD, CHRISTINE J | — |
| 17573559 | TETRAVALENT SYMMETRIC BISPECIFIC ANTIBODIES | STONEBRAKER, ALYSSA RAE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257749 | ANTI-BCMA ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SAOUD, CHRISTINE J | 1645 | §112 | Non-Final OA | — | Pending | Jun 15, 2023 |
| 17573559 | TETRAVALENT SYMMETRIC BISPECIFIC ANTIBODIES | STONEBRAKER, ALYSSA RAE | 1671 | §103 | Non-Final OA | — | Pending | Jan 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWuhan Yzy Biopharma Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Christine J Saoud has the most, with 1 of Wuhan Yzy Biopharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
